ASTM-E2476 Historical Revision Information
Standard Guide for Risk Assessment and Risk Control as it Impacts the Design, Developm

ASTM-E2476 - 2009 EDITION - SUPERSEDED
Show Complete Document History

Document Center Inc. is an authorized dealer of ASTM standards.
The following bibliographic material is provided to assist you with your purchasing decision:

Standard Guide for Risk Assessment and Risk Control as it Impacts the Design, Development, and Operation of PAT Processes for Pharmaceutical Manufacture
ORDER

Scope

1.1 This document provides guidance on the assessment of risks to product quality within and related to PAT processes in the pharmaceutical industry. It addresses those risks to product quality arising from, associated with, identified by, or modified by the implementation of PAT in pharmaceutical development and manufacturing for primary, secondary, and biotech sectors of the industry. It does not replace those assessments of risk currently undertaken by pharmaceutical companies, but is, rather, an additional component focused specifically upon the evaluation and design of PAT processes. See Practice E 2474, Guide E 2500, and ICH Q8.

1.2 This standard does not purport to address all of the safety concerns, if any, associated with its use. It is the responsibility of the user of this standard to establish appropriate safety and health practices and determine the applicability of regulatory limitations prior to use. Note that safety in this context refers to operational and operator safety, not to patient safety.

Significance and Use

This guide is intended to provide guidance regarding the use of risk analysis in the development, day-to-day running, and continuous improvement of pharmaceutical processes incorporating Process Analytical Technology (PAT). Since PAT is defined as being risk-based (see FDA Guidance for Industry), it is important that a consistent approach to the use of risk methodologies is adopted, to ensure rapid transfer of process understanding within the development and manufacturing teams, and to the regulators where that is appropriate.

4.2 This guidance only covers those aspects of risk assessment related to risk to product quality. Other aspects (such as risk to patient) should be covered in the conventional manner.

Keywords

critical quality attribute (CQA); manufacturing; Process Analytical Technology (PAT); process understanding; risk management; ICS Number Code 11.120.10 (Medicaments)

To find similar documents by ASTM Volume:

14.01 (Healthcare Informatics)

14.02 (General Test Methods; Forensic Psychophysiology; Forensic Sciences; Terminology; Conformity Assessment; Statistical Methods; Nanotechnology; Forensic Engineering; Manufacture of Pharmaceutical Products)

To find similar documents by classification:

11.120.10 (Medicaments Including medical prescriptions and medicinal herbs)

This document comes with our free Notification Service, good for the life of the document.

This document is available in either Paper or PDF format.

Document Number

ASTM-E2476-09

Revision Level

2009 EDITION

Status

Superseded

Modification Type

New

Publication Date

Aug. 1, 2009

Document Type

Guide

Page Count

10 pages

Committee Number

E55.01